Floatz logo

AZD 8186

Triple Negative Breast Cancer TNBC

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

448 Active assets in the Triple Negative Breast Cancer TNBC cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Atezolizumab
European Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

AZD 8186 is also rated in:

castration-resistant prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
prostate cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →